High-level results from the interim analysis of the DESTINY-Breast09 Phase III trial indicate that Enhertu (trastuzumab deruxtecan) combined with pertuzumab significantly improves progression-free survival (PFS) compared to taxane, trastuzumab, and pertuzumab (THP) as a first-line treatment for HER2-positive metastatic breast cancer. The improvement was observed across all pre-specified patient subgroups. While overall survival data is not yet mature, early trends favor the Enhertu combination. The trial also includes an ongoing arm assessing Enhertu monotherapy versus THP. HER2-positive metastatic breast cancer affects 15-20% of patients with metastatic breast cancer, and most experience disease progression within two years of first-line treatment with THP. The safety profile of Enhertu in combination with pertuzumab aligns with the known profiles of each therapy.
— new from AstraZeneca